Zhitong Finance App News, Lizhu Pharmaceutical (01513.HK) issued an announcement. Recently, the company's subsidiary, Sichuan Everbright Pharmaceutical Co., Ltd. (Sichuan Everbright), received the “Drug Clinical Trial Approval Notice” (Notice No.: 2026LP03296) approved by the State Drug Administration to carry out clinical trials of “vestibular migraine (this product)” as declared by Sichuan Guangda.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.